Revolution Medicines, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Revolution Medicines received FDA approval for RASONQUE (daraxonrasib) on August 26, 2026, for metastatic pancreatic cancer, generating $197.6M in net product revenue in Q3 2026 (five weeks of sales) from >5,000 patients. The European Medicines Agency's CHMP adopted a positive opinion recommending approval. The company received a mandatory $250M debt tranche from Royalty Pharma triggered by FDA approval and elected not to draw an optional $250M tranche. Cash position reached $3.7B as of September 30, 2026 (excluding the October $250M receipt).
Why this rating
First commercial revenue ($198M annualized from 5 weeks ≈ 3% of $6.7B market cap) validates clinical program and transforms company from clinical-stage to commercial. EU approval pathway imminent. However, Q3 revenue includes finite early-launch dynamics (EAP transition, stocking); longer-term trajectory uncertain. Significant but not transformational given company scale and pipeline continuation.
Price action (we called it positive)
before filing · preread $11.38 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.